Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma

Autor: Adrienne van Beckhoven, Thomas A. Davis, Ronald Levy, Claudia Benike, Frank J. Hsu, Tina Marie Liles, Clemens B. Caspar, Edgar G. Engleman, Debra K. Czerwinski, Behnaz Taidi
Rok vydání: 2001
Předmět:
Idiotype
Male
Squalene
Lymphoma
B-Cell
Transplantation Conditioning
Cyclophosphamide
Antibodies
Neoplasm
Polysorbates
Receptors
Antigen
B-Cell
Lymphocyte Activation
Transplantation
Autologous
Disease-Free Survival
Immune system
Antigen
Adjuvants
Immunologic
Immunoglobulin Idiotypes
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Ifosfamide
B-cell lymphoma
Bone Marrow Transplantation
Etoposide
Transplantation
Immunity
Cellular
business.industry
Vaccination
Hematology
Dendritic Cells
medicine.disease
Acquired immune system
Carmustine
Combined Modality Therapy
Lymphoma
Antibodies
Anti-Idiotypic
Treatment Outcome
Drug Resistance
Neoplasm
Immunology
Hemocyanins
Feasibility Studies
Female
Safety
business
Acetylmuramyl-Alanyl-Isoglutamine
Whole-Body Irradiation
medicine.drug
Follow-Up Studies
Zdroj: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 7(9)
ISSN: 1083-8791
Popis: Vaccination with the idiotype (Id) protein derived from B-cell malignancies can produce Id-specific immune responses that correlate with improved remission duration and survival rates in patients with follicular non-Hodgkin's lymphoma (NHL). A state of minimal or no residual disease correlates strongly with the laboratory detection of a cellular or humoral immune response. High-dose cytotoxic therapy (HDCT) with autologous stem cell support (autologous bone marrow transplantation [ABMT]) can provide profound cytoreduction of B-cell NHL, but the potential immune suppression associated with myeloablative therapy may compromise a patient's ability to mount a specific immune response. To determine whether patients with NHL could mount detectable immuneresponses following ABMT, Id vaccines were administered at 2 to 12 months following myeloablative therapy to a series of patients with relapsed or resistant B-cell NHL. Two different vaccination strategies produced robust immune responses against KLH in all patients, supporting the capacity of the reconstituted immune system following HDCT to react against a strong antigen. Combining the results from both vaccination strategies, 10 of 12 patients mounted Id-specific humoral or cellular responses. Vaccinations were consistently well tolerated. Of the 12 patients, 7 have experienced prolonged remissions with a follow-up from HDCT ranging from 3 to more than 11 years. Our experience serves to document the ability of the recovering immune system to react against both self and xenotypic antigens and supports the feasibility and safety of antigen-specific vaccination following myeloablative therapy in patients with B-cell NHL.Biol Blood Marrow Transplant 2001;7(9):517-22.
Databáze: OpenAIRE
Externí odkaz: